ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Tennessee's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1990
Musings on TOPS Membership
Meetings & Education
TOPS Advocacy Support
Financial Advocacy & Patient Assistance
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
TOPS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Nivolumab for Previously Treated SCLC Patients
On August 17, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response (DOR).
Read the BMS press release here.
Read the FDA announcement her
Tweets by OSSatACCC